BR112018068055A2 - métodos para produção de proteínas de fusão de toxina da difteria monoméricas livre de agregados e usos terapêuticas - Google Patents
métodos para produção de proteínas de fusão de toxina da difteria monoméricas livre de agregados e usos terapêuticasInfo
- Publication number
- BR112018068055A2 BR112018068055A2 BR112018068055A BR112018068055A BR112018068055A2 BR 112018068055 A2 BR112018068055 A2 BR 112018068055A2 BR 112018068055 A BR112018068055 A BR 112018068055A BR 112018068055 A BR112018068055 A BR 112018068055A BR 112018068055 A2 BR112018068055 A2 BR 112018068055A2
- Authority
- BR
- Brazil
- Prior art keywords
- dna
- methods
- fusion proteins
- diphtheria toxin
- therapeutic uses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção é um vetor de expressão de dna compreendendo: um toxp; um toxo mutante que bloqueia a regulação mediada por fe da expressão gênica; e uma sequência de dna que codifica uma proteína, em que o toxp e o toxo mutante regulam a expressão do segmento de dna que codifica a proteína. é preferido que os vetores de expressão de dna da presente invençao incluam sequências de dna que codifiquem um peptídeos inal, de modo a que uma proteína expressão seja ligada ao peptídeo sinal antes do processamento. novas proteínas são produzidas a partir do vetor de expressão de dna da presente invenção.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662306281P | 2016-03-10 | 2016-03-10 | |
PCT/US2017/021715 WO2017156356A1 (en) | 2016-03-10 | 2017-03-10 | Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018068055A2 true BR112018068055A2 (pt) | 2019-01-08 |
Family
ID=59789900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018068055A BR112018068055A2 (pt) | 2016-03-10 | 2017-03-10 | métodos para produção de proteínas de fusão de toxina da difteria monoméricas livre de agregados e usos terapêuticas |
Country Status (12)
Country | Link |
---|---|
US (1) | US10988512B2 (pt) |
EP (1) | EP3426785A4 (pt) |
JP (2) | JP2019512233A (pt) |
KR (1) | KR102430891B1 (pt) |
CN (1) | CN109790545A (pt) |
AU (1) | AU2017230792B2 (pt) |
BR (1) | BR112018068055A2 (pt) |
CA (1) | CA3017143A1 (pt) |
IL (2) | IL261660A (pt) |
MX (1) | MX2018010850A (pt) |
WO (2) | WO2017156356A1 (pt) |
ZA (1) | ZA201806450B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
EP3762401A4 (en) * | 2018-03-06 | 2021-12-08 | The Johns Hopkins University | CANCER TREATMENT OR PREVENTION METHODS USING TREG DEPLETING AGENT AND CHECKPOINT INHIBITOR |
US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
EP3845556A1 (fr) * | 2019-12-31 | 2021-07-07 | Peptinov SAS | Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l interleukine-6 |
WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
KR20230102682A (ko) * | 2021-12-30 | 2023-07-07 | (주)셀트리온 | 목적 단백질의 발현 방법 |
CN114903896B (zh) * | 2022-05-30 | 2023-07-25 | 广西大学 | 贝达喹啉在制备治疗弓形虫病药物中的应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2549855B1 (fr) | 1983-07-29 | 1987-03-27 | Grp Genie Genetique | Sequence nucleotidique codant pour le peptide signal de la toxine diphterique, vecteur contenant cette sequence nucleotidique, leur application a la transformation de micro-organismes et compositions peptidiques obtenues |
US6022950A (en) | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
CA1340494C (en) | 1988-05-19 | 1999-04-13 | The Beth Israel Hospital Association And Brigham And Women's Hospital | Induction of tolerance to a foreign antigen |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
WO1991013090A1 (en) | 1990-03-02 | 1991-09-05 | Diane Williams | Improved chimeric toxins |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
NO175188C (no) * | 1990-06-27 | 1994-09-14 | Sjur Olsnes | Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
WO1993000077A1 (en) | 1991-06-21 | 1993-01-07 | University Of Cincinnati | Orally administrable therapeutic proteins and method of making |
US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
DE69312487T2 (de) | 1992-05-18 | 1997-11-27 | Minnesota Mining & Mfg | Einrichtung zur transmucosalen wirkstoffabgabe |
US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
DE69434079T2 (de) | 1993-03-05 | 2005-02-24 | Wyeth Holdings Corp. | Plasmid zur Herstellung von CRM-Protein und Diphtherie-Toxin |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5654273A (en) | 1994-09-22 | 1997-08-05 | Children's Medical Center Corporation | Synducin mediated modulation of tissue repair |
US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
US6737514B1 (en) | 1998-12-22 | 2004-05-18 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
AU2003278694A1 (en) | 2002-05-22 | 2004-02-02 | Advanced Microbial Solutions Corporation | Gene expression using metal ion dependent repressor/operator tandems |
EP2457577A1 (en) * | 2003-11-25 | 2012-05-30 | Anjin Corporation | Diphtheria toxin variant |
JP5052338B2 (ja) * | 2005-06-21 | 2012-10-17 | 一般財団法人阪大微生物病研究会 | 癌治療薬 |
GB2451928B (en) | 2007-06-21 | 2011-03-16 | Angelica Therapeutics Inc | Modified Toxins |
EP2600843B9 (en) * | 2010-07-19 | 2020-03-11 | Pressure BioSciences, Inc. | Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy |
WO2012039954A2 (en) * | 2010-09-08 | 2012-03-29 | The Scripps Research Institute | Reliable stabilization of n-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns |
WO2012110596A1 (en) * | 2011-02-16 | 2012-08-23 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Fusion protein for the treatment of immunologic or allergic reactions |
MX346245B (es) | 2011-06-01 | 2017-03-13 | Univ Xiamen | Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria. |
US8906681B2 (en) * | 2011-08-02 | 2014-12-09 | The Scripps Research Institute | Reliable stabilization of N-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns |
-
2017
- 2017-03-10 EP EP17764163.6A patent/EP3426785A4/en active Pending
- 2017-03-10 JP JP2018547409A patent/JP2019512233A/ja active Pending
- 2017-03-10 WO PCT/US2017/021715 patent/WO2017156356A1/en active Application Filing
- 2017-03-10 BR BR112018068055A patent/BR112018068055A2/pt not_active Application Discontinuation
- 2017-03-10 CA CA3017143A patent/CA3017143A1/en active Pending
- 2017-03-10 KR KR1020187029101A patent/KR102430891B1/ko active IP Right Grant
- 2017-03-10 CN CN201780025215.0A patent/CN109790545A/zh active Pending
- 2017-03-10 AU AU2017230792A patent/AU2017230792B2/en active Active
- 2017-03-10 MX MX2018010850A patent/MX2018010850A/es unknown
- 2017-03-10 US US16/083,848 patent/US10988512B2/en active Active
- 2017-09-11 WO PCT/US2017/051020 patent/WO2018164712A1/en active Application Filing
-
2018
- 2018-09-06 IL IL261660A patent/IL261660A/en unknown
- 2018-09-27 ZA ZA2018/06450A patent/ZA201806450B/en unknown
-
2022
- 2022-03-22 IL IL291586A patent/IL291586A/en unknown
- 2022-11-04 JP JP2022177061A patent/JP2023011857A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2019512233A (ja) | 2019-05-16 |
EP3426785A4 (en) | 2019-12-25 |
ZA201806450B (en) | 2020-12-23 |
IL261660A (en) | 2018-10-31 |
US20190071472A1 (en) | 2019-03-07 |
IL291586A (en) | 2022-05-01 |
CN109790545A (zh) | 2019-05-21 |
EP3426785A1 (en) | 2019-01-16 |
MX2018010850A (es) | 2019-05-15 |
AU2017230792B2 (en) | 2023-08-10 |
WO2017156356A1 (en) | 2017-09-14 |
US10988512B2 (en) | 2021-04-27 |
JP2023011857A (ja) | 2023-01-24 |
CA3017143A1 (en) | 2017-09-14 |
KR20190016934A (ko) | 2019-02-19 |
AU2017230792A1 (en) | 2018-10-18 |
AU2017230792A8 (en) | 2018-11-29 |
KR102430891B1 (ko) | 2022-08-09 |
WO2018164712A1 (en) | 2018-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018068055A2 (pt) | métodos para produção de proteínas de fusão de toxina da difteria monoméricas livre de agregados e usos terapêuticas | |
BR112019007433A2 (pt) | sistemas de replicon de vírus recombinante e usos dos mesmos | |
BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
BR112019010699A2 (pt) | receptores de células t e imunoterapia empregando os mesmos | |
MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
AU2018298422A1 (en) | Novel nucleic acid molecules | |
BR112015017800A2 (pt) | moléculas de ligação ao antígeno biespecífica ativadora de célula t, polinucleotídeo, polipeptídeo, vetor, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t | |
BR112019010972A2 (pt) | receptores de células t e imunoterapia usando os mesmos | |
EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
CR20230026A (es) | Proteínas de fusión gdf15 y usos de estas (divisional 2018-0532) | |
BR112017017293A2 (pt) | método para predizer modificações de aminoácidos, para selecionar e/ou classificar modificações de aminoácidos e para fornecer uma vacina e vacina | |
BR112018000835A2 (pt) | molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo | |
EA201992609A1 (ru) | Слитые белки, содержащие интерлейкин-2, и их применения | |
BR112017008165A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
BR112016004472A2 (pt) | proteínas de ligação ao antígeno de gitr | |
PH12019500122A1 (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
CY1124667T1 (el) | Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα | |
MX2017014730A (es) | Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3). | |
MX2018009225A (es) | Inmunoterapia basada en vectores de distribución personalizados y usos de la misma. | |
WO2015198243A3 (en) | Compositions and methods for long acting proteins | |
BR112017025728A2 (pt) | fragmentos mutantes da proteína ras | |
CL2021002168A1 (es) | Péptido asociado a tumor; ácido nucleico; vector de expresión; célula huésped recombinante; método para producir el péptido; linfocitos t activados y su método de producción; anticuerpo; tcr; uso para tratar el cáncer; kit y composición farmacéutica; método para producir vacuna; y áptaro (divisional solicitud no. 201702407). | |
BR112017018703A2 (pt) | peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno | |
NZ752941A (en) | Frataxin expression constructs | |
BR112018010887A2 (pt) | polipeptídeo de fusão |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |